The Precivity™ blood tests aid healthcare providers in the diagnosis and treatment of Alzheimer’s disease
Indications for Testing
The PrecivityAD2™/PrecivityAD® blood tests are intended for use in patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.
The Precivity-ApoE™ blood test is indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
Only a healthcare provider can order the Precivity™ tests.
Aβ42/40 Ratio + p-tau217/np-tau217 Ratio (Test Code 1001)
The PrecivityAD2™ test measures specific amyloid beta (Aβ) and tau peptide concentrations in the blood to calculate a likelihood score – the Amyloid Probability Score 2 (APS2). The APS2 determines whether a patient is:
• Positive (has high likelihood) or
• Negative (has low likelihood)
for the presence of brain amyloid plaques by amyloid PET scan. The Precivity-ApoE™ blood test can be performed concurrently on the same submitted blood sample with the PrecivityAD2™ test.
(Test Code 2001) The PrecivityAD2™ + Precivity-ApoE™ test
(Test Code 2002) The PrecivityAD2™ reflex to Precivity-ApoE™ test
The PrecivityAD2™ Blood Test Specifications
ApoE E2, E3, E4 (Test Code 1003)
The Precivity-ApoE™ blood test measures apolipoprotein E (ApoE) isoforms to determine the presence of E2, E3, and/or E4 alleles. This provides the patient’s ApoE proteotype, which corresponds to APOE genotype and can help healthcare providers with treatment decisions.
The Precivity-ApoE™ Blood Test Specifications
Aβ42/40 Ratio + ApoE Proteotype + Age (Test Code 1002)
The PrecivityAD® test measures specific amyloid beta (Aβ) and apolipoprotein E (ApoE) peptides in the blood and combines this information with a patient's age to calculate the Amyloid Probability Score (APS). The APS determines whether a patient has:
• Low likelihood
• High likelihood or
• Intermediate likelihood
for the presence of brain amyloid plaques by amyloid PET scan. ApoE proteotype, which corresponds to APOE genotype, is included in the PrecivityAD® test report.
The PrecivityAD® Blood Test Specifications
How it Works:
Step 1:
Patient blood sample is collected using a Precivity™ test kit*
Step 2:
Sample is processed and shipped to C₂N for analysis
Step 3:
Test report is sent to healthcare provider
*The Precivity™ test kits include everything needed to draw blood samples and ship to C₂N.
To order the Precivity™ tests, please click here:
Published data on the Precivity™ tests can be found at: https://precivityad.com/publications
If you have any questions, please call 1.877.226.3424
The C₂N laboratory is a CLIA-certified, CAP-accredited laboratory that performs the Precivity™ tests as Laboratory Developed Tests (LDT). C₂N received a Breakthrough Device Designation from the FDA in June 2018.